The application of RAGE and GECKO in cell-based target discovery screens

Pharmacogenomics

Volumn 6, Issue 4, 2005, Pages 383-392

  Brunden, K R ^a   Sherf, B A ^a   Harrington, J J ^a  

^a ATHERSYS INC   (United States)

Author keywords

Drug targets; Gene expression; Genetics; Knockout; Libraries; Screens

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BEVACIZUMAB; BINDING PROTEIN; CARBOHYDRATE BINDING PROTEIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 6; CD69 ANTIGEN; CHIMERIC PROTEIN; CISPLATIN; COMPLEMENTARY DNA; COMPLEMENTARY RNA; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; ECTODYSPLASIN A2 RECEPTOR; EZETIMIBE; GENE PRODUCT; HYGROMYCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; ISOPROTEIN; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; PACLITAXEL; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEIN TYROSINE KINASE; PROTEINASE INHIBITOR; RECEPTOR PROTEIN; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SIMVASTATIN; SMALL INTERFERING RNA; TAK1 BINDING PROTEIN 3; TOLL LIKE RECEPTOR 5; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; BACTERIAL INFECTION; CANCER COMBINATION CHEMOTHERAPY; CELL ASSAY; DISEASE COURSE; DRUG SYNTHESIS; DRUG TARGETING; GENE FUNCTION; GENE IDENTIFICATION; GENE LIBRARY; GENE OVEREXPRESSION; GENE TECHNOLOGY; GENETIC SCREENING; GENOME WIDE CELLULAR KNOCKOUT; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; INVERSE POLYMERASE CHAIN REACTION; KNOCKOUT GENE; MAMMAL CELL; METHODOLOGY; OPEN READING FRAME; PHENOTYPIC VARIATION; PROTEIN FUNCTION; RANDOM ACTIVATION OF GENE EXPRESSION; REVIEW; SEQUENCE ANALYSIS;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GENOME; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; ORGANISMS, GENETICALLY MODIFIED; PHARMACOGENETICS;

EID: 21444448876     PISSN: 14622416     EISSN: None     Source Type: Journal    
DOI: 10.1517/14622416.6.4.383     Document Type: Review

References (38)

1. Zambrowicz BP, Sands AT: Knockouts model the 100 best-selling drugs; will they model the next 100? Nature Rev. Drug Discov. 2, 38-51 (2003).
2. Ratjen F, Doring G: Cystic fibrosis. Lancet 361, 681-689 (2003).
3. Khurana TS, Davies KE: Pharmacological strategies for muscular dystrophy. Nature Rev. Drug Discov. 2, 379-390 (2003).
4. Selkoe DJ, Podlisny MB: Deciphering the genetic basis of Alzheimer's disease. Annu. Rev. Genomics Hum. Genet. 3, 67-99 (2002).
5. Romero R, Kuivaniemi H, Tromp G, Olson J: The design, execution, and interpretation of genetic association studies to decipher complex diseases. Am. J. Obstet. Gynecol. 187, 1299-1312 (2002).
6. Glazier AM, Nadeau JH, Aitman TJ: Finding genes that underlie complex traits. Science 298, 2345-2349 (2002).
7. Zhang MQ: Extracting functional information from microarrays: a challenge for functional genomics. Proc. Natl Acad. Sci. USA 99, 12509-12511 (2002).
8. Butte A: The use and analysis of microarray data. Nat. Rev. Drug Discov. 1, 951-960 (2002).
9. Braasch DA, Corey DR: Novel antisense and peptide nucleic acid strategies for controlling gene expression. Biochemistry 41, 4503-4510 (2002).
10. Zheng L, Liu J, Batalov S et al.: An approach to genome wide screens of expressed small interfering RNAs in mammalian cells. Proc. Natl Acad. Sci. USA 101, 135-140 (2004).
11. Kawasaki H, Onuki R, Suyama E, Taira K: Identification of genes that function in the TNF-α-mediated apoptotic pathway using randomized hybrid ribozyme libraries. Nat. Biotechnol. 20, 376-380 (2002).
12. Hannon GJ, Rossi JJ: Unlocking the potential of the human genome with RNA interference. Nature 431, 371-378 (2004).
13. Pearlberg J, LaBaer J: Protein expression clone repositories for functional proteomics. Curr. Opin. Chem. Biol. 8, 98-102 (2004).
14. Harrington J, Sherf B, Rundlett S et al.: Creation of genome-wide protein expression libraries using random activation of gene expression. Nature Biotechnol. 19, 440-445 (2001).
15. Johnson JM, Castle J, Garrett-Engele P, et al.: Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays. Science 302, 2141-2144 (2003).
16. Kan Z, Rouchka EC, Gish WR, States DJ: Gene structure prediction and alternative splicing analysis using genomically aligned ESTs. Genome Res. 11, 889-900 (2001).
17. Cartegni L, Krainer A: Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat. Struct. Biol. 10, 120-125 (2003).
18. Maniatis T, Tasic B: Alternative pre-mRNA splicing and proteome expansion in metazoans. Nature 418, 236-243 (2002).
19. Jin G, Klika A, Callahan M, et al. Identification of a human NF-κB-activating protein, TAB3. Proc. Natl. Acad. Sci. USA 17, 2028-2033 (2004).
20. Moors MA, Li L, Mizel SB: Activation of interleukin-1 receptor-associated kinase by gram-negative flagellin. Infect. Immun. 69, 4424-4429 (2001).
21. Yan M, Wang LC, Hymowitz SG, et al.: Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors. Science 290, 523-527 (2000).
22. Ogura Y, Inohara N, Benito A, Chen FF, Yamaoka S, Nunez G: Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-B. J. Biol. Chem. 276, 4812-4818 (2001).
23. Li X, Commane M, Nie H et al.: Act1, an NF-κB-activating protein. Proc. Natl. Acad. Sci. USA 97, 10489-10493 (2000).
24. Cao Z, Xiong J, Takeuchi M, Kurama T, Goeddel DV: TRAF6 is a signal transducer for interleukin-1. Nature 3, 443-446 (1996).
25. Muzio M, Ni J, Feng P. Dixit VM: IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 278, 1612-1615 (1997).
26. Stehlik C, Hayashi H, Pio F, Godzik A, Reed JC: CARD6 is a modulator of NF-κB activation by Nod1-and Cardiak-mediated pathways. J. Biol. Chem. 278, 31941-31949 (2003).
27. Brown SD, Hardisty RE: Mutagenesis strategies for identifying novel loci associated with disease phenotypes. Semin. Cell. Dev. Biol. 14, 19-24 (2003).
28. Stanford WL, Cohn JB, Cordes SP: Genetrap mutagenesis: past, present and beyond. Nature Rev. Genet. 2, 756-768 (2001).
29. Blagosklonny MV: Analysis of FDA approved anticancer drugs reveals the future of cancer therapy. Cell Cycle 3, 1035-1042 (2004).
30. Johnson DH, Fehrenbacher L, Novotny WF et al.: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 22, 2184-2191 (2004).
31. Hurwitz H, Fehrenbacher L, Novotny W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
32. Portsmouth S, Stebbing J, Gazzard B: Current treatment of HIV infection. Curr. Top. Med. Chem. 3, 1458-1466 (2003).
33. Autran B, Carcelain G, Li TS et al.: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277, 112-116 (1997).
34. McHutchison JG, Fried MW. Current therapy for hepatitis C: pegylaxed interferon and ribavirin. Clin. Liver. Dis. 7, 149-161 (2003).
35. Stein GE, Gurwith MJ: Amoxicillin-potassium clavulanate, a β-lactamase-resistant antibiotic combination. Clin. Pharm. 3, 591-599 (1984).
36. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J: Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am. J. Cardiol. 93, 1487-1494 (2004).
37. Audhya A, Loewith R, Parsons AB et al.: Genome-wide lethality screen identifies new PI4, 5P(2) effectors that regulate the actin cytoskeleton. EMBO J. 29, 3747-3757 (2004).
38. Costigan C, Gehrung S, Snyder M: A synthetic lethal screen identifies SLK1, a novel protein kinase homolog implicated in yeast cell morphogenesis and cell growth. Mol. Cell. Biol. 12, 1162-1178 (1992).